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estosterone Therapy in
omen With Heart Failure
Why Can’t a Woman
e More Like a Man?”*
aul W. Armstrong, MD,
ustin A. Ezekowitz, MBBCH, MSC
dmonton, Alberta, Canada
n the near half-century since Alan Jay Lerner posed his
amous question in the play My Fair Lady, investigators
ave vigorously pursued the basis for sexual dimorphism (1).
ehavioral diversity, health outcomes, and longevity are
nly some of the distinctive features of the sexes often
ttributed to hormonal differences (2). The dramatic reduc-
ion in estradiol in women associated with menopause led to
he—apparently obvious—conclusion from epidemiologic
nd observational studies that estrogen replacement would
nhance post-menopausal cardiovascular health. When the
onverse was shown to be true in a randomized trial, this
onclusion led to a remarkable reversal in the guideline
ecommendations on hormone replacement therapy (3,4).
ecause testosterone also declines with age, its replacement
as garnered substantial attention, especially among men,
here it has been used to enhance lost muscle mass and
exual prowess as well as to augment athletic performance in
ompetitive sport. By contrast, in the therapy of prostate
ancer, androgen deprivation therapy is used (5).
See page 1310
The conventional excess of neurohormones as an apt
escriptor of the heart failure syndrome has undergone
ubstantial revision as new evidence points to down-
egulation of a variety of contributors, including steroid
ormones. As outlined by Sacca (6), testosterone is de-
reased in proportion to heart failure severity, an indepen-
ent predictor of death, and when replaced, seems to exert
beneficial metabolic affect on insulin resistance. The
bservations from Italian researchers, reported by Caminiti
t al. (7), using intramuscular injections of testosterone
Editorials published in the Journal of the American College of Cardiology reflect the
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From the University of Alberta, Edmonton, Alberta, Canada. The authors have
eported that they have no relationships to disclose.dded to optimal medical therapy in elderly men with
hronic heart failure support this paradigm, because they
howed in a randomized placebo-controlled trial that this
herapy improved exercise capacity, muscle strength, and
lucose metabolism. Because androgens also decline in
ging women, Iellamo et al. (8) (from the same Italian group
ho studied this issue in men) undertook a proof-of-
oncept investigation to assess whether low-dose testoster-
ne supplementation would benefit women with chronic
eart failure.
In this issue of the Journal, they report the results of
ransdermal testosterone supplementation in 36 elderly
omen. Patients were randomized in a 2:1 ratio to receive
ither a transdermal patch of 300-g testosterone or a
lacebo, applied twice weekly for 24 weeks; the primary end
oints were distance traversed in a 6-min walk test and
nsulin sensitivity by the homeostasis model. A significant
3% relative increase in 6-min walking time coupled with a
arallel increase in peak oxygen consumption (VO2) was
chieved, analogous to that found in their previous study
f men. So too was there a decline in insulin resistance in
he treated group, confirming the anticipated metabolic
hanges.
Although the authors of the current study assert a positive
orrelation between the change in free testosterone levels
nd the increase in walking time, much unexplained vari-
nce in this relationship exists. It would have been more
seful to have seen confirmation of their previous findings
hat demonstrated a relationship between change in testos-
erone levels and peak VO2 and maximal isometric muscle
trength. Therapies that improve lower limb muscle
trength and thus have the potential to improve exercise
olerance and reduce fatigue are sorely needed in heart
ailure. This need is greatest in elderly persons, who
onstitute a growing segment of the heart failure popula-
ion. Additional benefit to upper body strength (thus
llowing potential improvement in activities of daily living)
ould be a certain “win” for this treatment if assessed by
tandardized tools used in other fields. Fatigue remains the
ingle most difficult symptom to treat—limited improve-
ent in this troubling and pervasive symptom is seen with
urrent evidence-based therapies. Because there was no
arallel improvement in cardiac function or structure as
emonstrated by echocardiography in this and previous
tudies, it seems that a purely peripheral mechanism ac-
ounted for the enhanced exercise performance, akin to
hat might be expected with exercise training (7,8). At least
other potential factors might have contributed to the
unctional improvement associated with testosterone ther-
py in the current study: 1) because there was a 1.7-g rise in
emoglobin (and a commensurate 0.5-g decline in the
lacebo group), an improved oxygen-carrying capacity that
as been previously shown to modulate enhanced exercise
erformance and peak VO2 in heart failure could have been
perative (9); and 2) baroreceptor sensitivity might have
i
p
c
f
b
(
p
a
t
l
r
m
c
a
a
a
e
t
p
n
o
s
i
t
s
a
p
w
fi
e
p
f
M
R
2
C
R
1318 Armstrong and Ezekowitz JACC Vol. 56, No. 16, 2010
Testosterone Therapy in Women With HF October 12, 2010:1317–9mproved, as demonstrated in previous studies; this has the
otential to improve muscle sympathetic nerve activity with
oncomitant increased muscle arteriole vasodilation and
unction (7). Additionally, androgens are known to possess
oth anti-inflammatory and immunosuppressive effects
10). Future studies should include an examination of these
ossibilities.
No major side effects were evident with the 300-g patch
pplied twice weekly in the current trial, but it is noteworthy
hat this is a much smaller dose than that used in men, and
ong-term surveillance in larger numbers of patients will be
equired to evaluate its potential therapeutic role.
Figure 1 provides a suggested construct for the assess-
ent of novel heart failure therapies such as employed in the
urrent study. With this “bottom-up approach,” we have
rbitrarily scored the evidence acquired from the innovative
nd interesting work of Iellamo et al. (8), which represents
promising start for this new therapeutic direction. How-
ver, we have travelled down the path of potential new
reatments for heart failure many times and been disap-
ointed more often than pleased. To that end, more work
eeds to be done. We require further understanding of the
ptimal degree of androgen replacement—physiologic or
upraphysiologic—and how best to identify those requiring
t; we also need to know which clinically available metric is
he best gauge to follow. Hence, future studies should
Figure 1 Construct and Score Card for Evaluation of Novel The
ED  emergency department; HF  heart failure; KCCQ  Kansas City Cardiomyoystematically examine both differing doses and routes ofdministration of testosterone, include much larger patient
opulations of both sexes, explore other correlates that
ould provide insight into the mechanism and benefit, and
nally collect meaningful clinical outcome data that can
stablish its role and its potential promise in clinical
ractice.
Perhaps adding some androgens to women with heart
ailure will fulfill the hopes of Henry Higgins as expressed in
y Fair Lady!
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